Dr Reddy's Shares Drop 7% as Quality Issues Delay Weight-Loss Drug Launch

Source: Economictimes
Arth Insight · What this means for your wallet
- Higher medication costs likely: The delay of a potentially more affordable generic drug means you might continue to pay more for existing or branded weight-loss/diabetes treatments.
- Treatment options postponed: If you or a family member need this specific type of medication, its availability will be delayed, potentially impacting health management plans.
- No immediate general financial impact: Unless you are an investor in Dr. Reddy's shares, this particular stock market event won't directly affect your daily expenses or savings.
Shares of Dr Reddy’s Laboratories witnessed a sharp decline after the company paused commercial supplies of its semaglutide product. The delay stems from quality concerns regarding the active pharmaceutical ingredient (API) used in the drug.
- ▸Dr Reddy's has paused the supply of its semaglutide drug due to API quality concerns.
- ▸The stock price fell by 7% as investors reacted to the potential delay in market entry.
- ▸The company maintains that patient safety and regulatory filings are not at risk.
- ▸An internal investigation is underway to fix the production issue and resume supplies.
- ✓Dr Reddy's has paused the supply of its semaglutide drug due to API quality concerns.
- ✓The stock price fell by 7% as investors reacted to the potential delay in market entry.
- ✓The company maintains that patient safety and regulatory filings are not at risk.
- ✓An internal investigation is underway to fix the production issue and resume supplies.
Investors in Dr Reddy’s Laboratories faced a volatile trading session on Thursday as the company’s stock price tumbled by approximately 7%. The sell-off was triggered by an official announcement regarding the delay in the commercial rollout of its semaglutide product, a highly anticipated medication used in the treatment of type 2 diabetes and weight management.
The Root of the Delay
The pharmaceutical major confirmed that the delay is linked to a quality issue involving the Active Pharmaceutical Ingredient (API). The API is the primary biological component responsible for the drug's effect. While the company has not specified the exact nature of the defect, it has initiated a comprehensive investigation to identify the root cause and rectify the production line.
Impact on Patients and Regulatory Status
In a move to reassure stakeholders, Dr Reddy’s clarified that this development does not compromise patient safety, as the affected batches have not reached the retail market. Furthermore, the company stated that its existing regulatory filings remain unaffected. The primary impact is currently limited to the timeline of commercial availability and the immediate sentiment of the stock market.
Market Reaction and Outlook
The 7% slide reflects investor anxiety over the competitive landscape of the weight-loss drug market. Semaglutide is a high-demand molecule globally, and any delay in its supply chain could potentially allow competitors to gain a larger market share. Analysts are closely watching how quickly the company can restore its supply chain and whether this issue will lead to any long-term capital expenditure adjustments.
- The stock hit a session low following the news.
- Investigation is ongoing to restore supplies.
- No impact reported on other product portfolios.
This article is for informational purposes only and does not constitute financial or investment advice.
Some listings may be sponsored and Arth Vani may earn a referral fee. All information is for educational purposes only — verify terms and suitability with the provider before acting. Not financial advice.
Frequently Asked Questions
Why did Dr Reddy's share price fall today?
The shares fell by 7% after the company announced a delay in the commercial supply of its semaglutide product due to quality issues with the raw materials (API).
Is the drug semaglutide safe for current users?
Yes, the company stated that patient safety is unaffected as the quality issue was identified before the commercial supplies reached the public.
What is semaglutide used for?
Semaglutide is a medication primarily used for managing type 2 diabetes and is also widely used for weight loss treatment.
Join the Arth Vani channels
Daily news summaries, IPO & market alerts on Telegram and WhatsApp.
Because you read about Stock Market

Chubu Electric Invests ₹1,350 Cr in Continuum Green Energy
Japanese firm Chubu Electric Power has acquired a significant stake in Continuum Green Energy India for ₹1,350 crore. This investment aims to bolster India's renewable energy sector.
BreakingIndian Markets Near All-Time Highs, Decouple From Global Downturn
India's benchmark indices, Sensex and Nifty, are reportedly approaching their peak levels, signaling robust investor confidence and market performance. This upward momentum is notable as Indian markets appear to be 'decoupling' from a broader global market rout, positioning India as a unique performer among major global economies.

Five Lesser-Known Indian Stocks Showed Dividend Yields Up To 19.6% In FY26
Several Indian companies outside the major indices reportedly delivered exceptionally high dividend yields for the fiscal year 2026. CyberTech Systems led this group with a yield of 19.6%, highlighting potential income opportunities for retail investors looking beyond traditional blue-chip stocks.
Related Stories

Chubu Electric Invests ₹1,350 Cr in Continuum Green Energy
Japanese firm Chubu Electric Power has acquired a significant stake in Continuum Green Energy India for ₹1,350 crore. This investment aims to bolster India's renewable energy sector.
BreakingIndian Markets Near All-Time Highs, Decouple From Global Downturn
India's benchmark indices, Sensex and Nifty, are reportedly approaching their peak levels, signaling robust investor confidence and market performance. This upward momentum is notable as Indian markets appear to be 'decoupling' from a broader global market rout, positioning India as a unique performer among major global economies.

Five Lesser-Known Indian Stocks Showed Dividend Yields Up To 19.6% In FY26
Several Indian companies outside the major indices reportedly delivered exceptionally high dividend yields for the fiscal year 2026. CyberTech Systems led this group with a yield of 19.6%, highlighting potential income opportunities for retail investors looking beyond traditional blue-chip stocks.
BreakingNSE, PNB, GAIL Hit 52-Week Highs as Sensex Surges
Five BSE 200 stocks, including National Stock Exchange (NSE), Punjab National Bank (PNB), and GAIL, reached new 52-week highs on Thursday. This surge coincided with a significant rally in the broader market, with the Sensex gaining 990 points.